<DOC>
	<DOCNO>NCT02300831</DOCNO>
	<brief_summary>The recent development therapy target specific biomarkers mutation change standard care prognosis patient advance NSCLC , data currently available emerge biomarkers . In addition , correlation biomarkers patient ' clinical outcome standard care set poorly understood . This study aim address need .</brief_summary>
	<brief_title>LUMINIST : LUng Cancer Molecular Insights Non Interventional Study</brief_title>
	<detailed_description>The LUMINIST study enrol patient ineligible SELECT-1 ( NCT01933932 ) SELECT-2 ( NCT01750281 ) RCTs . Within NIS patient follow longitudinally treatment information outcome . The final dataset enable linkage individual patient level clinical information datasets collect within LUMINIST exploratory biomarker data generate sample collect part SELECT-1 screening . This enable examination various molecular marker patient v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog ( KRAS ) wild-type KRAS mutation positive ( KRAS+ ) patient . The LUMINIST study aim enable investigation various molecular segment NSCLC , base patient consent permit local legislation , yet discover . The availability longitudinal dataset clinical information link tumour sample valuable tool readily assess clinical utility potential new biomarkers . The determination current standard care outcomes future molecular segment interest provide valuable new insight scientific community .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<criteria>1 . Provision informed consent patient nextofkin decease patient study entry , mandate local regulation 2 . Female male adult ( accord country regulation age majority ) 3 . Patients eligible choose enter selumetinib SELECT1 SELECT2 trial 4 . Patients confirm histological diagnosis NSCLC 1 . Involved plan and/or conduct study ( applies AZ staff and/or staff study site )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>Lung Cancer</keyword>
	<keyword>SELECT-1</keyword>
	<keyword>SELECT-2</keyword>
	<keyword>selumetinib</keyword>
	<keyword>biomarker</keyword>
	<keyword>NIS</keyword>
	<keyword>Observational study</keyword>
	<keyword>Disease registry</keyword>
	<keyword>Clinical Outcomes</keyword>
</DOC>